Published in Arch Med Sci on December 26, 2013
Lipids, blood pressure and kidney update 2015. Lipids Health Dis (2015) 1.00
Heart function disturbances in chronic kidney disease - echocardiographic indices. Arch Med Sci (2014) 0.93
Iron metabolism in hemodialyzed patients - a story half told? Arch Med Sci (2014) 0.85
Markers of increased cardiovascular risk in patients with chronic kidney disease. Lipids Health Dis (2014) 0.84
The Relationship Between Hemodialysis and the Echocardiographic Findings in Patients with Chronic Kidney Disease. Med Arch (2016) 0.75
Is kidney function affecting the management of myocardial infarction? A retrospective cohort study in patients with normal kidney function, chronic kidney disease stage III-V, and ESRD. Int J Nephrol Renovasc Dis (2016) 0.75
Biochemical markers of type 2 diabetes as a late complication of myocardial infarction: a case-control study. Arch Med Sci (2017) 0.75
Neutrophil-to-lymphocyte ratio as a possible indicator of epicardial adipose tissue in patients undergoing hemodialysis. Arch Med Sci (2016) 0.75
Defining the role of trimetazidine in the treatment of cardiovascular disorders: some insights on its role in heart failure and peripheral artery disease. Drugs (2014) 0.75
Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med (2008) 19.76
Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med (2004) 19.42
Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med (2005) 12.72
Guidelines on myocardial revascularization. Eur Heart J (2010) 8.85
Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med (2001) 6.38
Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA (2005) 3.72
Acute myocardial infarction and renal dysfunction: a high-risk combination. Ann Intern Med (2002) 3.71
Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet (2006) 3.43
Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J (2004) 3.14
Influence of concurrent renal dysfunction on outcomes of patients with acute coronary syndromes and implications of the use of glycoprotein IIb/IIIa inhibitors. J Am Coll Cardiol (2003) 2.99
Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. J Am Coll Cardiol (2003) 2.52
ACE inhibitors and survival of hemodialysis patients. Am J Kidney Dis (2002) 2.37
First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. Am J Kidney Dis (2005) 2.36
Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation (2004) 2.33
Benefits of aspirin and beta-blockade after myocardial infarction in patients with chronic kidney disease. Am Heart J (2002) 2.17
The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol (2002) 2.03
Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation (2010) 1.96
Time for new indications for statins? Med Sci Monit (2009) 1.87
Relation between renal function, presentation, use of therapies and in-hospital complications in acute coronary syndrome: data from the SWEDEHEART register. J Intern Med (2009) 1.65
Correlates of bleeding events among moderate- to high-risk patients undergoing percutaneous coronary intervention and treated with eptifibatide: observations from the PROTECT-TIMI-30 trial. J Am Coll Cardiol (2006) 1.65
Reperfusion in patients with renal dysfunction after presentation with ST-segment elevation or left bundle branch block: GRACE (Global Registry of Acute Coronary Events). JACC Cardiovasc Interv (2009) 1.56
Safety and efficacy of antiplatelet and antithrombotic therapy in acute coronary syndrome patients with chronic kidney disease. J Am Coll Cardiol (2011) 1.43
Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Ann Intern Med (2003) 1.39
Lipids, blood pressure, kidney - what was new in 2011? Arch Med Sci (2011) 1.37
HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int (2002) 1.29
beta-Blocker use in long-term dialysis patients: association with hospitalized heart failure and mortality. Arch Intern Med (2004) 1.14
IMproving the imPlemEntation of cuRrent guidelines for the mAnagement of major coronary hearT disease rIsk factors by multifactorial interVEntion. The IMPERATIVE renal analysis. Arch Med Sci (2011) 1.12
Reduction in atherosclerotic events: a retrospective study in an outpatient cardiology practice. Arch Med Sci (2012) 1.12
Risk factor reduction in progression of angiographic coronary artery disease. Arch Med Sci (2012) 1.08
World Kidney Day 2011 - Protect your kidneys, save your heart. Arch Med Sci (2011) 1.05
The risk of atherosclerosis in patients with chronic kidney disease. Int Urol Nephrol (2013) 1.03
Markers of kidney function in the elderly in relation to the new CKD-EPI formula for estimation of glomerular filtration rate. Arch Med Sci (2011) 1.01
Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy--a meta-analysis of 11 randomized controlled trials involving 21,295 participants. Pharmacol Res (2013) 1.00
Kidney transplant Medicare payments and length of stay: associations with comorbidities and organ quality. Arch Med Sci (2011) 0.99
A meta-analysis of the role of statins on renal outcomes in patients with chronic kidney disease. Is the duration of therapy important? Int J Cardiol (2013) 0.98
Relation between renal function and outcomes in patients with non-ST-segment elevation acute coronary syndrome: real-world data from the European Public Health Outcome Research and Indicators Collection Project. Arch Intern Med (2010) 0.97
The treatment of coronary artery disease in patients with chronic kidney disease. QJM (2006) 0.95
Assessing renal function - searching for the perfect marker continues! Arch Med Sci (2011) 0.94
The impact of renal dysfunction on outcomes in the ExTRACT-TIMI 25 trial. J Am Coll Cardiol (2007) 0.94
A comparison of clopidogrel responsiveness in patients with versus without chronic renal failure. Am J Cardiol (2009) 0.94
Renal insufficiency and mortality in patients with known or suspected coronary artery disease. J Am Soc Nephrol (2008) 0.90
Nephroprotective and clinical potential of statins in dialyzed patients. Expert Opin Ther Targets (2009) 0.88
Current problems in hypertension and nephrology. Expert Opin Pharmacother (2010) 0.88
The cardio-renal-anaemia syndrome predicts survival in peritoneally dialyzed patients. Arch Med Sci (2010) 0.86
Role and significance of statins in the treatment of hypertensive patients. Curr Med Res Opin (2009) 0.86
Does coronary artery bypass graft surgery improve survival among patients with end-stage renal disease? Ann Thorac Surg (2006) 0.85
Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors? Med Sci Monit (2009) 0.85
Long-term fluvastatin reduces the hazardous effect of renal impairment on four-year atherosclerotic outcomes (a LIPS substudy). Am J Cardiol (2005) 0.84
Statins in patients with chronic kidney disease: why, who and when? Expert Opin Pharmacother (2010) 0.84
Prevention of sudden cardiac death in patients with chronic kidney disease. BMC Nephrol (2012) 0.84
Vascular adhesion protein-1 and renalase in regard to diabetes in hemodialysis patients. Arch Med Sci (2012) 0.84
Effects of statins on lipid profile in chronic kidney disease patients: a meta-analysis of randomized controlled trials. Curr Med Res Opin (2013) 0.83
Is plasma urotensin II concentration an indicator of myocardial damage in patients with acute coronary syndrome? Arch Med Sci (2012) 0.83
Clinical trials update from the European Society of Cardiology Heart Failure meeting: SHAPE, BRING-UP 2 VAS, COLA II, FOSIDIAL, BETACAR, CASINO and meta-analysis of cardiac resynchronisation therapy. Eur J Heart Fail (2004) 0.82
The relation of renal function to ischemic and bleeding outcomes with 2 different glycoprotein IIb/IIIa inhibitors: the do Tirofiban and ReoPro Give Similar Efficacy Outcome (TARGET) trial. Am Heart J (2005) 0.82
Acute coronary syndromes in patients with chronic kidney disease. Curr Vasc Pharmacol (2013) 0.82
Chronic kidney disease in acute coronary syndromes. World J Nephrol (2012) 0.81
FOSIDIAL: a randomised placebo controlled trial of the effects of fosinopril on cardiovascular morbidity and mortality in haemodialysis patients. Study design and patients' baseline characteristics. Fundam Clin Pharmacol (2002) 0.79
Impact of chronic aspirin and statin therapy on presentation of patients with acute myocardial infarction and impaired renal function. Prev Cardiol (2010) 0.79
Treatment effects of eptifibatide in planned coronary stent implantation in patients with chronic kidney disease (ESPRIT Trial). Am J Cardiol (2003) 0.79
Statins in patients with chronic kidney disease - an attempt at recommendations. Curr Med Res Opin (2013) 0.79
Management of coronary artery disease in patients with chronic kidney disease. Adv Perit Dial (2009) 0.78
Reduced blood platelet sensitivity to aspirin in coronary artery disease: are dyslipidaemia and inflammatory states possible factors predisposing to sub-optimal platelet response to aspirin? Basic Clin Pharmacol Toxicol (2006) 0.78
Pre-CKD- do we need another hero? Curr Vasc Pharmacol (2014) 0.78
The implications of renal impairment among patients undergoing percutaneous coronary intervention. J Invasive Cardiol (2002) 0.76
Predictive Value for Galectin 3 and Cardiotrophin 1 in Hemodialysis Patients. Angiology (2016) 0.76